溶血磷脂酸在结直肠癌发生发展中的机制研究

doi:10.11904/j.issn.1002-3070.2020.03.017

Abstract

Abstract: In recent years,the importance of autotaxin-lysophosphatidic acid(ATX-LPA)signaling pathway in the development of colorectal cancer has gradually been widely recognized by the medical community.LPA signals can induce various cellular processes including wound healing,differentiation,proliferation,migration,and survival through at least 6 G Protein-coupled receptors(GPCRs),that is,LPA_1-6.It is very important to maintain the function of intestinal epithelial barrier and promote the survival,proliferation and metastasis of colorectal cancer cells.Therefore,this article reviews the relationship between the ATX-LPA signaling pathway and colorectal cancer-related inflammation discovered in recent years,and the effect of colorectal cancer-related inflammation discovered in recent years,and the effect of this signaling pathway on the development of colorectal cancer.It also reviews LPA and related molecules in colorectal cancer treatment and predicting prospects.

Key words: Lysophosphatidic acid, Colorectal cancer, Signal pathway, Inflammation, Treatment prospects

CLC Number:

R735.3

LU Xuemei,LI Yuntao,AN Jinhui,JI Guozhong. The mechanism of lysophosphatidic acid in the development of colorectal cancer[J]. Journal of Practical Oncology, 2020, 34(3): 276-281.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.03.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I3/276

References

1 Arnold M,Sierra MS,Laversanne M,et al.Global patterns and trends in colorectal cancer incidence and mortality[J].Gut,2017,66(4):683-691.
2 Zheng RS,Sun KX,Zhang SW,et al.Report of cancer epidemiology in China,2015[J].Zhonghua Zhong Liu Za Zhi,2019,41(1):19-28.
3 Peterson LW,Artis D.Intestinal epithelial cells:regulators of barrier function and immune homeostasis[J].Nat Rev Immunol,2014,14(3):141-153.
4 Balkwill F,Mantovani A.Inflammation and cancer:back to Virchow?[J].Lancet,2001,357(9255):539-545.
5 Kappelman MD,Farkas DK,Long MD,et al.Risk of cancer in patients with inflammatory bowel diseases:a nationwide population-based cohort study with 30 years of follow-up evaluation[J].Clin Gastroenterol Hepatol,2014,12(2):265-273.
6 Bottazzi B,Riboli E,Mantovani A.Aging,inflammation and cancer[J].Semin Immunol,2018,40:74-82.
7 Valdes-Rives SA,Gonzalez-Arenas A.Autotaxin-lysophosphatidic acid:from inflammation to cancer development[J].Mediators Inflamm,2017,2017:9173090.
8 Yun CC.Lysophosphatidic acid and autotaxin-associated effects on the initiation and progression of colorectal cancer[J].Cancers(Basel),2019,11(7):958.
9 Benesch MGK,Tang X,Venkatraman G,et al.Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo[J].J Biomed Res,2016,30(4):272-284.
10 Gonzalezgil I,Zian D,Vazquezvilla H,et al.The status of the lysophosphatidic acid receptor type 1(LPA1R)[J].Med Chem Comm,2015,6(1):13-23.
11 Taniguchi R,Inoue A,Sayama M,et al.Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6[J].Nature,2017,548(7667):356-360.
12 Chun J,Hla T,Lynch KR,et al.International union of basic and clinical pharmacology LXXVIII lysophospholipid receptor nomenclature[J].Pharmacol Rev,2010,62(4):579-587.
13 Imielinski M,Baldassano RN,Griffiths A,et al.Common variants at five new loci associated with early-onset inflammatory bowel disease[J].Nat Genet,2009,41(12):1335-1340.
14 Farooq SM,Hou Y,Li H,et al.Disruption of GPR35 exacerbates dextran sulfate sodium-induced colitis in mice[J].Dig Dis Sci,2018,63(11):2910-2922.
15 Wang L,Zhou W,Zhong Y,et al.Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-kappaB signaling pathway[J].Mol Cancer,2017,16(1):61.
16 Choi JW,Herr DR,Noguchi K,et al.LPA receptors:subtypes and biological actions[J].Annu Rev Pharmacol Toxicol,2010,50:157-186.
17 Yun CC,Kumar A.Diverse roles of LPA signaling in the intestinal epithelium[J].Exp Cell Res,2015,333(2):201-207.
18 Colotta F,Allavena P,Sica A,et al.Cancer-related inflammation,the seventh hallmark of cancer:links to genetic instability[J].Carcinogenesis,2009,30(7):1073-1081.
19 Cai Y,Yousef A,Grandis JR,et al.NSAID therapy for PIK3CA-altered colorectal,breast,and head and neck cancer[J].Adv Biol Regul,2019,15:100653.
20 Tigyi GJ,Yue J,Norman DD,et al.Regulation of tumor cell -microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis[J].Adv Biol Regul,2019,71:183-193.
21 Kinzler KW,Vogelstein B.Lessons from hereditary colorectal cancer[J].Cell,1996,87(2):159-170.
22 Kazama S,Kitayama J,Aoki J,et al.Immunohistochemical detection of autotaxin(ATX)/lysophospholipase D(lysoPLD)in submucosal invasive colorectal cancer[J].J Gastrointest Cancer,2011,42(4):204-211.
23 Knowlden S,Georas SN.The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation[J].J Immunol,2014,192(3):851-857.
24 Yung YC,Stoddard NC,Chun J.LPA receptor signaling:pharmacology,physiology,and pathophysiology[J].J Lipid Res,2014,55(7):1192-1214.
25 Lin S,Wang D,Iyer S,et al.The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer[J].Gastroenterology,2009,136(5):1711-1720.
26 Lin S,Lee SJ,Shim H,et al.The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine[J].Am J Physiol Gastrointest Liver Physiol,2010,299(5):1128-1138.
27 Guo L,He P,No YR,et al.Kruppel-like factor 5 incorporates into the beta-catenin/TCF complex in response to LPA in colon cancer cells[J].Cell Signal,2015,27(5):961-968.
28 Zhang H,Bialkowska A,Rusovici R,et al.Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5[J].J Biol Chem,2007,282(21):15541-15549.
29 Li J,Xi W,Li X,et al.Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy[J].Bioorg Med Chem,2019,27(7):1145-1158.
30 Ha JH,Radhakrishnan R,Jayaraman M,et al.LPA induces metabolic reprogramming in ovariancancer via a pseudohypoxic response[J].Cancer Res,2018,78(8):1923-1934.
31 Lee SJ,No YR,Dang DT,et al.Regulation of hypoxia-inducible factor 1alpha(HIF-1alpha)by lysophosphatidic acid is dependent on interplay between p53 and kruppel-like factor 5[J].J Biol Chem,2013,288(35):25244-25253.
32 Ha JH,Ward JD,Radhakrishnan R,et al.Lysophosphatidic acid stimulates epithelial to mesenchymal transition markerslug/snail2 in ovarian cancer cells via Galphai2,Src,and HIF1alpha signaling nexus[J].Oncotarget,2016,7(25):37664-37679.
33 De Craene B,Berx G.Regulatory networks defining EMT during cancer initiation and progression[J].Nat Rev Cancer,2013,13(2):97-110.
34 Benesch MGK,Ko YM,Tang X,et al.Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer[J].Endocr Relat Cancer,2015,22(4):593-607.
35 Radhakrishnan R,Ha JH,Jayaraman M,et al.Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts[J].Cancer Lett,2019,442:464-474.
36 Seo EJ,Kwon YW,Jang IH,et al.Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism[J].Stem Cells,2016,34(3):551-564.
37 Brindley DN,Lin F,Tigyi G.Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy[J].Biochim Biophys Acta,2013,1831(1):74-85.
38 Li Y,Zhang W,Zhang J,et al.Plasma levels of lysophosphatidic acid in ovarian cancer versus controls:a meta-analysis[J].Lipids in Health & Disease,2015,14(1):72.
39 Benesch MG,Tang X,Venkatraman G,et al.Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo[J].J Biomed Res,2016,30(4):272-284.
40 Venkatraman G,Benesch MG,Tang X,et al.Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses:implications for cancer treatment[J].Faseb J,2015,29(3):772-785.
41 Miyabe C,Miyabe Y,Nagai J,et al.Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis[J].Arthritis Res Ther,2019,21(1):191.
42 Knowlden SA,Hillman SE,Chapman TJ,et al.Novel inhibitory effect of a lysophosphatidic acid 2 agonist on allergen-driven airway inflammation[J].Am J Respir Cell Mol Biol,2016,54(3):402-409.
43 Marshall JC,Collins JW,Nakayama J,et al.Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer[J].J Natl Cancer Inst,2012,104(17):1306-1319.
44 Ohashi T,Yamamoto T.Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin[J].Exp Dermatol,2015,24(9):698-702.
45 Nikitopoulou I,Kaffe E,Sevastou I,et al.A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis[J].PLoS One,2013,8(7):e70941.
46 Zhang H,Xu X,Gajewiak J,et al.Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo[J].Cancer Res,2009,69(13):5441-5449.
47 Schleicher SM,Thotala DK,Linkous AG,et al.Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature[J].PLoS One,2011,6(7):e22182.
48 Benesch MG,Tang X,Dewald J,et al.Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression[J].Faseb J,2015,29(9):3990-4000.
49 Leblanc R,Lee SC,David M,et al.Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone[J].Blood,2014,124(20):3141-3150.

[1]	ZHU Xiaoyun,ZHANG Yaning,MA Biping. Trend analysis of the death level and the probability of early death caused by colorectal cancer in Jinshan district,Shanghai,1980—2018 [J]. Journal of Practical Oncology, 2020, 34(3): 198-202.
[2]	WANG Fei, ZHU Benben. Effects of propofol on the proliferation,apoptosis and invasion of SCC-74 cells via HIF-1 α signal pathway [J]. Journal of Practical Oncology, 2020, 34(2): 120-125.
[3]	LI Bin, FENG Baoheng, YIN Fuxia, SU Wei. Establishment of a colorectal cancer xenograft model to study the bacterial infection in the intestine of mice and the mechanism of decitabine combined with cisplatin chemotherapy [J]. Journal of Practical Oncology, 2020, 34(2): 163-168.
[4]	ZENG Li, ZHUANG Shutong, DING Shihua, CHEN Chong, JIAO Lu, SUN Dayong. Molecular mechanisms of long non-coding RNA AFAP1-AS1 regulating the proliferation of colorectal cancer cells by PTEN/p-AKT signaling pathway [J]. Journal of Practical Oncology, 2020, 34(1): 11-16.
[5]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.
[6]	ZHANG Jinglan, LIU Ruibao. Progress in local interventional therapy for colorectal cancer with liver metastasis [J]. Journal of Practical Oncology, 2020, 34(1): 79-82.
[7]	LI Zhijie, ZHAO Qi, WU Huaxing. Research progress in the effects of intestinal microbes on colorectal cancer patients by metagenomics [J]. Journal of Practical Oncology, 2020, 34(1): 93-96.
[8]	ZHANG Yiwei, SHI Jing, LIU Yupeng, CAO Liming, HU Fulan, ZHAO Yashuang. Relationship between methylation of USP1 gene in peripheral blood and prognosis risk of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 420-424.
[9]	PU Rui, ZHU Lin, XIA Tingting, BI Haoran, SUN Hongru, HUANG Hao, ZHANG Lei, ZHAO Yashuang. Relationship between the methylation status of CpG island in STAT1,STAT3 gene promoters in peripheral blood and prognosis of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(4): 346-351.
[10]	FANG Xuan, CHEN Hongsheng, Li Guodong, LIU Ming. Advances in research on treatment of aberrant crypt foci [J]. Journal of Practical Oncology, 2019, 33(4): 376-379.
[11]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[12]	TONG Guanghai, TIAN Yang, WU Huaxing. Application of lipidomics in colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 179-192.
[13]	LIU Hengchen, ZHANG Xinyu. Toll-like receptor signaling pathway as a potential therapeutic target for colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 188-192.
[14]	LIU Hongtao, ZHANG Tongtong, LIU Yanjun. Research progress in the pathogenesis of obesity and colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 464-467.
[15]	WANG Zhi,LIU Zhongwei,ZENG Xueyun,SUI Mingjie,LIAO Jingyi,LI Yuehuan,HUANG Weidong,LIU Guoxiang. Health-related quality of life in patients with colorectal cancer precancerous lesions on EQ-5D-5L [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 320-326.

The mechanism of lysophosphatidic acid in the development of colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments